April 16, 2026 10:16 am (IST)
Follow us:
Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
New Delhi, June 23 (IBNS) Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Levofloxacin Tablets, 250mg and 500mg, the generic version of Levaquin Tablets (of Ortho-McNeil), which is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.
The total market size for Levofloxacin Tablets as per IMS is $28 Million per annum.
As on Mar 31, Jubilant Life Sciences had a total of 806 filings for formulations of which 368 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
FICCI appoints Anant Swarup as Secretary General
Wed, Apr 15 2026
Aditya Birla Capital Introduces ‘LeadHerShip’ to nurture next generation of women entrepreneurs in financial services
Wed, Apr 15 2026
LIC of India introduces MyLIC App. How will it benefit you?
Wed, Apr 15 2026
MTAR Technologies Ltd shares jump 10% on Bloom Energy–Oracle deal
Wed, Apr 15 2026
Market soars! Sensex, Nifty rally on West Asia hopes
Wed, Apr 15 2026